Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.48 |
| ▸ | SLCO1B3 | Q9NPD5 | 4/20 | 0.48 |
| ▸ | SLCO1B1 | Q9Y6L6 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | SLCO2B1 | O94956 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23202745 | 0.90 | PTPN1 (0.62) | DPP4PTPN1CYP3A4CYP2C9ALOX15 | |
| SCHEMBL21588131 | 0.85 | KDM4E (0.57) | CYP3A4CYP2C9ALOX15SLCO1B3SLCO1B1 | |
| SCHEMBL21588115 | 0.85 | KDM4E (0.53) | DPP4CYP3A4CYP2C9ALOX15SLCO1B3 | |
| SCHEMBL21588098 | 0.85 | CYP3A4 (0.58) | DPP4PTPN1CYP3A4CYP2C9ALOX15 | |
| SCHEMBL26481102 | 0.85 | DPP4 (0.49) | DPP4PTPN1CYP3A4CYP2C9ALOX15 | |
| SCHEMBL21588158 | 0.85 | CYP3A4 (0.51) | DPP4CYP3A4CYP2C9ALOX15SLCO1B3 | |
| SCHEMBL21588107 | 0.82 | DPP4 (0.52) | DPP4PTPN1CYP3A4CYP2C9ALOX15 | |
| SCHEMBL21588113 | 0.82 | CYP2C9 (0.49) | DPP4CYP3A4CYP2C9ALOX15SLCO1B3 | |
| SCHEMBL21588101 | 0.82 | DPP4 (0.46) | DPP4CYP3A4CYP2C9ALOX15SLCO1B3 | |
| SCHEMBL21588110 | 0.81 | CYP2C9 (0.60) | DPP4PTPN1CYP3A4CYP2C9ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643405-B2 | Compound for treatment or prevention of liver diseases | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2023-05-09 | — | — | US | claimed |
| CN-110183431-B | Compound for treating or preventing liver diseases | 江苏新元素医药科技有限公司 | 2023-04-11 | — | — | CN | claimed |
| US-20210246126-A1 | COMPOUND FOR TREATMENT OR PREVENTION OF LIVER DISEASES | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2021-08-12 | — | — | US | claimed |
| EP-3805216-A1 | COMPOUNDS FOR TREATMENT OR PREVENTION OF LIVER DISEASES | Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. (CN) | 2021-04-14 | — | — | EP | claimed |
| US-11643405-B2 | Compound for treatment or prevention of liver diseases | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2023-05-09 | — | — | US | disclosed |
| US-11643405-B2 | Compound for treatment or prevention of liver diseases | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2023-05-09 | — | — | US | disclosed |
| US-11643405-B2 | Compound for treatment or prevention of liver diseases | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2023-05-09 | — | — | US | disclosed |
| CN-110183431-B | Compound for treating or preventing liver diseases | 江苏新元素医药科技有限公司 | 2023-04-11 | — | — | CN | disclosed |
| US-20210246126-A1 | COMPOUND FOR TREATMENT OR PREVENTION OF LIVER DISEASES | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2021-08-12 | — | — | US | disclosed |
| US-20210246126-A1 | COMPOUND FOR TREATMENT OR PREVENTION OF LIVER DISEASES | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2021-08-12 | — | — | US | disclosed |
| EP-3805216-A1 | COMPOUNDS FOR TREATMENT OR PREVENTION OF LIVER DISEASES | Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. (CN) | 2021-04-14 | — | — | EP | disclosed |
| EP-3805216-A1 | COMPOUNDS FOR TREATMENT OR PREVENTION OF LIVER DISEASES | Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. (CN) | 2021-04-14 | — | — | EP | disclosed |
| WO-2019233440-A1 | COMPOUND FOR TREATMENT OR PREVENTION OF LIVER DISEASES | 江苏新元素医药科技有限公司 (CN) | 2019-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246126-A1 | COMPOUND FOR TREATMENT OR PREVENTION OF LIVER DISEASES | SLC10A1, GYS2, CPT1A | DPP4 626/4885PTPN1 3257/4885CYP3A4 187/4885 |
| US-11643405-B2 | Compound for treatment or prevention of liver diseases | SLC10A1, GYS2, CPT1A | DPP4 626/4885PTPN1 3257/4885CYP3A4 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.